Davita Inc vs ThredUp Inc — how do they compare? Davita Inc trades at $178.35 (market cap $11.38B), while ThredUp Inc trades at $3.09 (market cap $415.01M). The key difference: Davita Inc is far larger — about 27.4× ThredUp Inc's market cap, and Davita Inc is trading nearer its 52-week high, ThredUp Inc nearer its low. Which is the better fit depends on your goals.
| DVA | TDUP | |
|---|---|---|
Market Cap | $11.38B | $415.01M |
Sector | Health | Consumer Cyclical |
52-Week High | $240.96 | $12.08 |
52-Week Low | $103.87 | $3.11 |
Enterprise Value | $24.10B | $413.19M |
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $181.72, down 1.07% on the day, with technical indicators showing a mixed but overall bullish signal. The stock has consistently beaten earnings expectations in recent quarters, with Q2 2026 EPS of $4.02 surpassing estimates. Revenue growth is steady, reaching $13.64B in 2025, though net income margin has fluctuated. Analyst sentiment is cautiously optimistic with a consensus price target of $232.25, representing significant upside potential from current levels.
The outlook for DVA is positive, driven by strong volume growth and strategic execution, but faces risks from reimbursement pressures and a high debt load. Investment opportunity lies in the valuation discount to analyst targets and consistent earnings beats, while key risks include payer mix challenges and macroeconomic factors affecting healthcare spending.
ThredUp (TDUP) trades at $3.08, down 4.64% amid a bearish technical signal. The company reported Q2 2026 revenue growth of 16.9% to $90.8 million but missed EPS estimates and cut full-year revenue guidance, triggering a sharp stock decline. Despite a high gross margin of 79.52%, the firm remains unprofitable with a net income margin of -6.65%. Analyst consensus is positive with 57% buy ratings, but recent news highlights shareholder investigations and promotional headwinds.
The outlook is clouded by near-term execution risks and persistent losses, though long-term potential exists if the company can leverage its asset-light model and AI tools to achieve profitability. Key risks include competitive pressures, macroeconomic sensitivity, and the need to improve cost management. Investors should weigh analyst optimism against the company's challenging path to sustained earnings.
Trailing returns across standard periods
Latest headlines on both assets
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →ThredUp Inc is an online resale platform for women and kids apparel, shoes, and accessories. It generates revenue from items that are sold to buyers through the website, mobile app, and RaaS partners.
Read more on TDUP →